Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more
From BioSpace · · 24 min
This plays from the publisher's own server. We do not host a copy.
Not rated yet
Description
New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this week, including Novartis’ nearly $8 billion bet on mRNA drugs with China’s Abogen Biosciences; and could Sarepta Therapeutics turn things around from last year’s annus horribilis?